Skip to main content

Table 1 Baseline characteristics of the PADVa cohort and population-based cohort

From: Are the results from a multiplex proteomic assay and a conventional immunoassay for NT-proBNP and GDF-15 comparable?

 

PADVa n = 437

Population-based n = 643

Age (years)

70.0 ± 7.2

66.2 ± 9.5

Female sex

179 (41.0%)

192 (29.9%)

Ever smoked

331 (75.9%)

350(54.4%)

Body mass index (kg/m2)

27.1 ± 4.2

26.6 ± 3.6

Hypertension

336 (77.4%)

226 (35.1%)

Diabetes mellitus

110 (25.2%)

45 (7.0%)

Myocardial infarction

80 (18.3%)

21 (3.2%)

TIA/Stroke

44 (10.1%)

25 (3.9%)

Total cholesterol (mmol/L)

4.6 ± 1.2

5.6 ± 1.1

Creatinine (umol/L)

81 (69–97)

79 (69–90)

HbA1c (mmol/mol)

42.5 ± 10.7

37.9 ± 7.1

ICA stenosis

 

No stenosis

22 (0.5%)

30–50% stenosis

196 (44.9%)

50–70% stenosis

70 (16.0%)

 > 70% stenosis/occlusion

62 (14.2%)

Abnormal ABI

255 (58.4%)

LVEF < 45%

24 (5.5%)

11 (1.7%)

Medication

 ACE-I

153 (35.1%)

73 (11.4%)

 Statin

354 (81.2%)

111 (17.3%)

 Aspirin

338 (77.5%)

117 (18.2%)

 Betablocker

224 (51.4%)

130 (20.2%)

 GDF-15 (NPX)

10.1 (9.6–10.6)

9.5(9.1–10.0)

 GDF-15 (ng/L)

1379 (979–2083)

1027 (762–1377)

 NT-proBNP (NPX)

5.1 (4.0–6.0)

3.7 (2.8–4.6)

 NT-proBNP (ng/L)

169 (89–345)

77 (40–148.5)

  1. Values are mean ± standard deviation, median (25th percentile-75th percentile), or frequency (percentage)